Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-escalation study of bosutinib in patients with ALS
jRCT1090220419Phase 1Completed
- Sponsor
- Kyoto University
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bosutinib in amyotrophic lateral sclerosis (ALS) (4 arms), sponsored by Kyoto University. Primary endpoint: Dose limiting toxicity (DLT). Started Mar 2019; status: completed.
02
Drugs
bosutinib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT1090220419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1090220419.